IN2012DN03187A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03187A IN2012DN03187A IN3187DEN2012A IN2012DN03187A IN 2012DN03187 A IN2012DN03187 A IN 2012DN03187A IN 3187DEN2012 A IN3187DEN2012 A IN 3187DEN2012A IN 2012DN03187 A IN2012DN03187 A IN 2012DN03187A
- Authority
- IN
- India
- Prior art keywords
- present
- glp
- treat
- muscle atrophy
- prevent muscle
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 3
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
- 206010028289 Muscle atrophy Diseases 0.000 abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
- 230000020763 muscle atrophy Effects 0.000 abstract 2
- 201000000585 muscular atrophy Diseases 0.000 abstract 2
- 230000035764 nutrition Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that allows it to treat, limit or prevent muscle atrophy. Embodiments of the present invention are directed at GLP-2 containing compositions and to compositions that stimulate the secretion of GLP-2 in a body to treat or prevent muscle atrophy.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172398A EP2311486A1 (en) | 2009-10-07 | 2009-10-07 | GLP-2 for use in intestine and muscle recovery |
| PCT/EP2010/065021 WO2011042501A2 (en) | 2009-10-07 | 2010-10-07 | The intestine and muscle recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03187A true IN2012DN03187A (en) | 2015-09-25 |
Family
ID=41611235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3187DEN2012 IN2012DN03187A (en) | 2009-10-07 | 2010-10-07 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120270786A1 (en) |
| EP (2) | EP2311486A1 (en) |
| JP (1) | JP5801814B2 (en) |
| CN (1) | CN102711803B (en) |
| AU (1) | AU2010305420B2 (en) |
| BR (1) | BR112012009380A2 (en) |
| CA (1) | CA2776964C (en) |
| DK (1) | DK2485756T3 (en) |
| ES (1) | ES2539917T3 (en) |
| IN (1) | IN2012DN03187A (en) |
| WO (1) | WO2011042501A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014170245A1 (en) * | 2013-04-15 | 2014-10-23 | Nestec S.A. | Use of whey protein in combination with electrical muscle stimulation |
| JP6325215B2 (en) * | 2013-08-29 | 2018-05-16 | テルモ株式会社 | Nutrition frozen dessert |
| CN106793806A (en) * | 2014-10-14 | 2017-05-31 | 雀巢产品技术援助有限公司 | Improvement to the muscle function of elderly men |
| KR101661332B1 (en) * | 2015-05-28 | 2016-09-29 | (의료)길의료재단 | Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1 receptor agonist |
| US10993993B2 (en) | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
| KR102119188B1 (en) * | 2018-11-13 | 2020-06-08 | 이뮤노포지 주식회사 | Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1, GLP-1 derived peptide, or GLP-1 degradation inhibitor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5661123A (en) * | 1995-01-17 | 1997-08-26 | Nestec, Ltd. | Enteral composition for malabsorbing patients |
| US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6852690B1 (en) * | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| DE69716905T2 (en) * | 1996-04-12 | 2003-07-24 | 1149336 Ontario Inc., Toronto | ANALOGS OF THE GLUCAGON-LIKE PEPTIDES -2 |
| CA2223198A1 (en) * | 1997-01-14 | 1998-07-14 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
| CA2236519C (en) * | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| EP1090636A1 (en) * | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | High lipid diet |
| ES2310192T3 (en) * | 2000-09-18 | 2009-01-01 | Sanos Bioscience A/S | USE OF GLP-2 PEPTIDES. |
| US7186683B2 (en) * | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| PT1360202E (en) * | 2001-02-16 | 2008-09-01 | Conjuchem Biotechnologies Inc | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| KR20050059258A (en) * | 2002-10-14 | 2005-06-17 | 노보 노르디스크 에이/에스 | Glp-2 compounds, formulations, and uses thereof |
| US20040115708A1 (en) * | 2002-10-28 | 2004-06-17 | Ardies C. Murray | Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia |
| ATE549028T1 (en) * | 2003-05-15 | 2012-03-15 | Tufts College | STABLE ANALOGUES OF GLP-1 |
| CA2601427C (en) * | 2005-04-06 | 2013-06-11 | Novartis Ag | A method and composition for nutritionally improving glucose control and insulin action |
| WO2007080149A2 (en) * | 2006-01-09 | 2007-07-19 | Nestec S.A. | Treatment of stressed patients |
| NZ576260A (en) * | 2006-11-08 | 2012-04-27 | Zealand Pharma As | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2 |
-
2009
- 2009-10-07 EP EP09172398A patent/EP2311486A1/en not_active Withdrawn
-
2010
- 2010-10-07 WO PCT/EP2010/065021 patent/WO2011042501A2/en active Application Filing
- 2010-10-07 BR BR112012009380-0A patent/BR112012009380A2/en not_active Application Discontinuation
- 2010-10-07 IN IN3187DEN2012 patent/IN2012DN03187A/en unknown
- 2010-10-07 EP EP10762684.8A patent/EP2485756B1/en active Active
- 2010-10-07 US US13/500,784 patent/US20120270786A1/en not_active Abandoned
- 2010-10-07 ES ES10762684.8T patent/ES2539917T3/en active Active
- 2010-10-07 AU AU2010305420A patent/AU2010305420B2/en active Active
- 2010-10-07 JP JP2012532595A patent/JP5801814B2/en active Active
- 2010-10-07 DK DK10762684.8T patent/DK2485756T3/en active
- 2010-10-07 CA CA2776964A patent/CA2776964C/en active Active
- 2010-10-07 CN CN201080055259.6A patent/CN102711803B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102711803B (en) | 2017-02-22 |
| ES2539917T3 (en) | 2015-07-07 |
| AU2010305420A1 (en) | 2012-05-10 |
| WO2011042501A2 (en) | 2011-04-14 |
| AU2010305420B2 (en) | 2015-03-19 |
| EP2485756B1 (en) | 2015-05-20 |
| WO2011042501A3 (en) | 2011-06-03 |
| JP5801814B2 (en) | 2015-10-28 |
| CA2776964A1 (en) | 2011-04-14 |
| CN102711803A (en) | 2012-10-03 |
| EP2485756A2 (en) | 2012-08-15 |
| BR112012009380A2 (en) | 2021-06-22 |
| JP2013507341A (en) | 2013-03-04 |
| EP2311486A1 (en) | 2011-04-20 |
| US20120270786A1 (en) | 2012-10-25 |
| CA2776964C (en) | 2019-03-05 |
| DK2485756T3 (en) | 2015-06-08 |
| HK1173949A1 (en) | 2013-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268519A (en) | Compositions useful in treatment of spinal muscular atrophy | |
| IN2012DN01638A (en) | ||
| MX343135B (en) | Fumagillol type compounds and methods of making and using same. | |
| IN2012DN02624A (en) | ||
| IL210810A0 (en) | Compositions for the treatment of pain and/or inflamtion | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| JO2975B1 (en) | Composition for improving sexual wellness | |
| MY153948A (en) | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | |
| MX2011007930A (en) | Crystalline insulin-conjugates. | |
| EP2384198A4 (en) | Pharmaceutical compositions and methods of treating neurological insults | |
| MX337575B (en) | Sulphone compounds for use in the treatment of obesity. | |
| IN2012DN00624A (en) | ||
| IL184312A0 (en) | Herbal compositions for the treatment of diabetes and/or conditions associated therewith | |
| PH12013502261A1 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| HK1221171A1 (en) | Compositions for use in stimulating bone growth | |
| TN2012000059A1 (en) | Compositions comprising tramadol and celecoxib in the treatment of pain | |
| IN2012DN03187A (en) | ||
| ZA201109086B (en) | Prevention and treatment of allergic diarrhoea | |
| WO2011044523A3 (en) | Compositions and methods for treating obesity | |
| MX2011011860A (en) | Immune stimulating composition comprising an extract of aronia sp. in combination with selenium and/or zinc. | |
| MX2016005092A (en) | Vaginal inserted estradiol pharmaceutical compositons and methods. | |
| MX2015005733A (en) | Tricyclic compounds for use in the treatment and/or control of obesity. | |
| EP2597949A4 (en) | Sub-micron compositions | |
| PL2375912T3 (en) | Compositions and methods for the treatment of throat discomfort | |
| MX2018007398A (en) | Composition for improving mouthfeel. |